Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer.

ABSTRACT: Ovarian cancer is the most lethal gynecological malignancy worldwide although exponential progress has been made in its treatment over the last decade. New agents and novel combination treatments are on the horizon. Among many new drugs, a series of PI3K/AKT/mTOR pathway (referred to as the PI3K pathway) inhibitors are under development or already in clinical testing. The PI3K pathway is frequently upregulated in ovarian cancer and activated PI3K signaling contributes to increased cell survival and chemoresistance. However, no significant clinical success has been achieved with the PI3K pathway inhibitor(s) to date, reflecting the complex biology and also highlighting the need for combination treatment strategies. DNA damage repair pathways have been active therapeutic targets in ovarian c

SUBMITTER: Huang TT 

PROVIDER: S-EPMC7272282 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature